Invizius

Invizius is a private, clinical-stage medical device company targeting a critical unmet need in hemodialysis: the harmful immune reactions triggered when blood contacts the artificial surfaces of the dialysis circuit. The company's lead technology, H-Guard®, is a single-use, disposable device that aims to 'pre-condition' a patient's blood at the start of dialysis to prevent these inflammatory responses. By mitigating these reactions, Invizius aims to reduce long-term cardiovascular damage, improve patient quality of life, and lower associated healthcare costs for the growing global dialysis population.

H-Guard®: A single-use medical device that pre-conditions a patient's blood at the start of dialysis to transiently modulate the complement system and prevent instant blood-mediated inflammatory reactions (IBMIR).

There are currently no approved direct competitors addressing the IBMIR in dialysis. However, large dialysis equipment and consumable manufacturers (e.g., Fresenius, Baxter) have immense market control and R&D resources. Other risks include systemic anti-inflammatory drugs used in other indications being repurposed, though they lack the targeted, extracorporeal approach of Invizius.